Articles

The use of real-world evidence can prevent pharma companies from performing studies based on flawed data.

Building Effective Real World Evidence Studies to Support New Indications for Established Products

Blenrep significantly extended the time to disease progression or death against existing care methods as a second-line treatment for relapsed or refractory multiple myeloma. 

Phase 3 Trial for GSK’s Blenrep Yields Positive Results in Relapsed or Refractory Multiple Myeloma 

JAMA study investigates whether consuming energy drinks was associated with adverse pregnancy outcomes and whether caffeine consumption affects fetal-growth restriction. 

Research Explores Adverse Outcomes From Energy Drink Intake Before, During Pregnancy 

AbbVie acquiring all outstanding shares of ImmunoGen, Inc. for $31.26 per share, valuing the company at a total equity value of approximately $10.1 billion. 

AbbVie to Acquire ImmunoGen With its Platinum-Resistant Ovarian Cancer Drug Elahere

Supplemental new drug application for roflumilast cream 0.15% to treat atopic dermatitis in patients 6 years of age and older was assigned a Prescription Drug User Fee Act target action date of July 07, 2024.

FDA Accepts Arcutis Biotherapeutics' sNDA for Roflumilast Cream for Atopic Dermatitis

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but serious and potentially fatal reaction linked to use of antiseizure medications.

FDA Issues Warning of Potential Adverse Events Associated With Antiseizure Drugs

KarXT (xanomeline-trospium) is currently in development to treat schizophrenia and psychosis related to Alzheimer disease. 

FDA Accepts New Drug Application for Karuna Therapeutics' Novel Schizophrenia Drug

Vivos becomes the first company to bring to market an alternative to continuous positive airway pressure (CPAP) or surgical neurostimulation implants for patients with severe OSA.

Vivos Therapeutics' Obstructive Sleep Apnea Oral Appliance Gains FDA 510(k) Clearance 

The CDC’s Morbidity and Mortality Weekly Report show pediatric influenza hospitalization rates returned to levels that preceded the COVID-19 pandemic.

'High Severity' Flu Season Among Children Spotlights Importance of Vaccination

The FDA will investigate all currently approved CAR T-cell treatments, as well as BCMA-directed and CD19-directed genetically modified autologous CAR T-cell therapies, for the risk of secondary T-cell malignancies.

News